


PHARMACEUTICAL 2022



ROCKET PHARMACEUTICALS INC. Rank 208 of 475





PHARMACEUTICAL 2022



ROCKET PHARMACEUTICALS INC. Rank 208 of 475

The relative strengths and weaknesses of ROCKET PHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ROCKET PHARMACEUTICALS INC. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 91% points. The greatest weakness of ROCKET PHARMACEUTICALS INC. is the variable Research and Development, reducing the Economic Capital Ratio by 78% points.

The company's Economic Capital Ratio, given in the ranking table, is -69%, being 207% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	392,059
Cost of Goods Sold	0
Intangible Assets	30,815
Liabilities, Current	22,167
Liabilities, Non-Current	985
Other Assets	51,847
Other Compr. Net Income	-119
Other Expenses	2,977
Other Liabilities	19,144
Other Net Income	-1,912
Property and Equipment	22,299
Research and Development	125,476
Revenues	3,068
Selling, General and Administrative Expense	41,772

Output Variable	Value in 1000 USD
Assets	497,020
Liabilities	42,296
Expenses	170,225
Stockholders Equity	454,724
Net Income	-169,069
Comprehensive Net Income	-169,128
Economic Capital Ratio	-69%